Australia seems poised to gain access to a groundbreaking medication for excess weight: Retatrutide. The dual molecule – acting on both GLP-1 and GIP receptors – demonstrates promising efficacy in clinical studies, suggesting considerable decreases in BMI. While regulatory clearance hasn't occurred with TGA, a number of people dealing with obes